Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Robins and Rubinstein sold significant stock, though company beat earnings estimates.
Adaptive Biotechnologies (NASDAQ: ADPT) saw two top executives sell significant stock holdings recently.
CEO Chad Robins sold about $566,000 in shares, while COO Julie Rubinstein sold nearly $4.1 million.
The sales occurred under pre-arranged trading plans.
Despite these insider sales, the company reported strong financial results, beating earnings estimates with rising revenue.
Analysts remain divided on the stock's future performance.
10 Articles
Robins y Rubinstein vendieron importantes acciones, aunque la compañía superó las estimaciones de ganancias.